Chimerix (NASDAQ:CMRX) Rating Lowered to Sell at Zacks Investment Research

Zacks Investment Research lowered shares of Chimerix (NASDAQ:CMRX) from a hold rating to a sell rating in a research report sent to investors on Tuesday morning, Zacks.com reports.

According to Zacks, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. “

Several other research firms also recently issued reports on CMRX. ValuEngine raised shares of Chimerix from a sell rating to a hold rating in a report on Thursday, August 1st. Cowen reaffirmed a hold rating and set a $3.00 price objective on shares of Chimerix in a report on Thursday, May 9th. Finally, HC Wainwright upped their price objective on shares of Chimerix from $5.00 to $7.00 and gave the stock a buy rating in a report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of $4.00.

CMRX stock opened at $2.20 on Tuesday. Chimerix has a 12 month low of $1.74 and a 12 month high of $4.40. The firm has a 50 day moving average of $3.28 and a two-hundred day moving average of $2.87.

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.18). The firm had revenue of $1.44 million for the quarter, compared to the consensus estimate of $2.30 million. Chimerix had a negative return on equity of 38.70% and a negative net margin of 729.02%. On average, equities research analysts predict that Chimerix will post -1.1 EPS for the current fiscal year.

In other news, Director Martha J. Demski acquired 18,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The stock was acquired at an average cost of $3.60 per share, with a total value of $64,800.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 9.40% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of CMRX. SG Americas Securities LLC boosted its holdings in shares of Chimerix by 105.4% during the 1st quarter. SG Americas Securities LLC now owns 20,590 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 10,567 shares during the period. Quantitative Systematic Strategies LLC bought a new stake in shares of Chimerix during the 2nd quarter worth $67,000. Susquehanna International Group LLP acquired a new position in Chimerix during the 2nd quarter valued at $92,000. Prudential Financial Inc. acquired a new position in Chimerix during the 2nd quarter valued at $104,000. Finally, Marshall Wace LLP acquired a new position in Chimerix during the 1st quarter valued at $166,000. 57.68% of the stock is owned by institutional investors and hedge funds.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

See Also: What is a Special Dividend?

Get a free copy of the Zacks research report on Chimerix (CMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.